The effect of an SGLT2 inhibitor on sleep apnea in obese patients with sleep apnea syndrome and type 2 diabetes mellitus.

The effect of an SGLT2 inhibitor on sleep apnea in obese patients with sleep apnea syndrome and type 2 diabetes mellitus. - The effect of Canagliflozin on sleep apnea in obese patients with sleep apnea syndrome and type 2 diabetes mellitus.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020854

Enrollment

Registered

2016-02-03

Start date

2016-02-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus with sleep apnea syndrome

Interventions

Treatment with canagliflozin(100mg/day, everyday, 6 months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with an HbA1c level more than 6.5%. 2) Patients with BMI more than 25 kg/m2. 3) Patients recieved dietary and exercise treatment for more than 8 weeks. 4) Patients who understand the protocol of this study and are able to give written informed consent based on their own decision.

Exclusion criteria

Exclusion criteria: 1) Women in pregnacy, with breastfeeding or possibility of pregnancy. 2) Patients suffered from severe ketosis or diabetic coma in the past 6 months. 3) Patients with contraindication to canagliflozin administration. 4) Patients with serum creatine levels more than 1.5mg/dL. 5) Patients with critical illness such as severe heart failure, respiratory failure and malignacy. 6) Patients with treatment with insulin, GLP-1 analogue or other SGLT2 inhibitors. 7) Patients who are considered unsuitable for this study by responsible investigators of this study,

Design outcomes

Primary

Measure	Time frame
Apnea-hypopnea index after treatment with canagliflozin for 6 months	—

Countries

Japan

Contacts

Public ContactToshihiro Ichiki

Harasanshin Hospital Cardiology

ichiki@cardiol.med.kyushu-u.ac.jp092-291-3434

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026